HomeTrialNCT03877796
🔬NCT03877796RECRUITING

Clinical Pre-screening Protocol for Ovarian Cancer

Study Summary

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment60 participants
Primary Completion
Lead SponsorAllarity Therapeutics
Data Retrieved2026-04-11 02:53:24.471096+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.